Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.79 |
| ▸ | MEN1 | O00255 | 3/20 | 0.79 |
| ▸ | MAPT | P10636 | 3/20 | 0.79 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.79 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.79 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.79 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.79 |
| ▸ | HTR2B | P41595 | 1/20 | 0.79 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.79 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.79 |
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.56 |
| ▸ | PARP1 | P09874 | 2/20 | 0.55 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7831044 | 0.98 | LMNA (0.77) | LMNAKMT2AMEN1MAPTNR1I2 | |
| Hydrochloric Acid SCHEMBL1239153 | 0.98 | LMNA (0.77) | LMNAKMT2AMEN1MAPTNR1I2 | |
| Oxalic Acid SCHEMBL27771077 | 0.95 | LMNA (0.72) | LMNAKMT2AMEN1MAPTNR1I2 | |
| Formic Acid SCHEMBL5396723 | 0.94 | LMNA (0.70) | LMNAKMT2AMEN1MAPTNR1I2 | |
| SCHEMBL6835723 | 0.91 | LMNA (0.88) | LMNAKMT2AMEN1MAPTNR1I2 | |
| Pentalamide SCHEMBL30575479 | 0.90 | LMNA (0.97) | LMNAKMT2AMEN1MAPTNR1I2 | |
| Pentalamide SCHEMBL1262590 | 0.90 | LMNA (0.97) | LMNAKMT2AMEN1MAPTNR1I2 | |
| Exalamide SCHEMBL151112 | 0.88 | LMNA (1.00) | LMNAKMT2AMEN1MAPTNR1I2 | |
| SCHEMBL5147507 | 0.88 | LMNA (1.00) | LMNAKMT2AMEN1MAPTNR1I2 | |
| SCHEMBL873025 | 0.88 | LMNA (1.00) | LMNAKMT2AMEN1MAPTNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101602706-A | New Azabicyclic compounds, their preparation method and the medicinal compositions that contains them | SERVIER LAB (FR) | 2009-12-16 | — | — | CN | claimed |
| US-20090264412-A1 | Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | claimed |
| US-20090137574-A1 | Combination Therapy Using an 11Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor and an Antihypertensive Agent for the Treatment of Metabolic Syndrome and Related Diseases and Disorders | NOVO NORDISK A/S (DK) | 2009-05-28 | — | — | US | claimed |
| US-20080108598-A1 | Pharmaceutical use of substituted amides | NOVO NORDISK A/S (DK) | 2008-05-08 | — | — | US | claimed |
| EP-1912970-A2 | ACYLTRYPTOPHANOLS FOR FERTILITY CONTROL | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-04-23 | — | — | EP | claimed |
| EP-1862181-A2 | Combination therapy using an 11B-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | NOVO NORDISK A/S (DK) | 2007-12-05 | — | — | EP | claimed |
| EP-1854487-A2 | Combinations of an 11-beta-hydroxysteroid dehaydrogenase type 1 inhibitor and a glucocorticoid receptor agonist | Novo Nordisk A/S (DK) | 2007-11-14 | — | — | EP | claimed |
| WO-2007017289-A2 | ACYLTRYPTOPHANOLS FOR FERTILITY CONTROL | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | WO | claimed |
| US-20060111366-A1 | Pharmaceutical use of substituted amides | NOVO NORDISK A/S (DK) | 2006-05-25 | — | — | US | claimed |
| US-20060111348-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | NOVO NORDISK A/S (DK) | 2006-05-25 | — | — | US | claimed |
| EP-1084122-A1 | TETRAHYDRONAPHTHYRIDINYL-CARBOXAMIDES HAVING ANTI-CONVULSANT ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2001-03-21 | — | — | EP | claimed |
| WO-2001002366-A2 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS INTICONVULSANTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-01-11 | — | — | WO | claimed |
| EP-1042296-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 2000-10-11 | — | — | EP | claimed |
| EP-0993439-A1 | 4-BROMO OR 4-IODO PHENYLAMINO BENZHYDROXAMIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-04-19 | — | — | EP | claimed |
| WO-2000009486-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSIVANTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-02-24 | — | — | WO | claimed |
| WO-2000008020-A2 | TRICYCLIC CARBOXAMIDES | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-02-17 | — | — | WO | claimed |
| WO-1999065903-A1 | TETRAHYDRONAPHTHYRIDINYL-CARBOXAMIDES HAVING ANTI-CONVULSANT ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1999-12-23 | — | — | WO | claimed |
| WO-1999031068-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1999-06-24 | — | — | WO | claimed |
| WO-1999001426-A1 | 4-BROMO OR 4-IODO PHENYLAMINO BENZHYDROXAMIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-01-14 | — | — | WO | claimed |
| WO-1998037881-A1 | METHOD OF TREATING OR PREVENTING SEPTIC SHOCK BY ADMINISTERING A MEK INHIBITOR | WARNER LAMBERT COMPANY (US) | 1998-09-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108598-A1 | Pharmaceutical use of substituted amides | HSD11B1, HSD3B1, HSD11B2 | LMNA 3468/4885KMT2A 3134/4885MEN1 2380/4885 |
| US-20090137574-A1 | Combination Therapy Using an 11Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor and an Antihypertensive Agent for the Treatment of Metabolic Syndrome and Related Diseases and Disorders | HSD11B1, HSD11B2, HSD17B1 | LMNA 2005/4885KMT2A 3018/4885MEN1 1615/4885 |
| US-20060111348-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | HSD11B1, HSD11B2, HSD17B1 | LMNA 2005/4885KMT2A 3018/4885MEN1 1615/4885 |
| US-20090264412-A1 | Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy | HSD11B1, HSD17B1, NR3C1 | LMNA 4249/4885KMT2A 3419/4885MEN1 2970/4885 |
| US-20060111366-A1 | Pharmaceutical use of substituted amides | HSD11B1, HSD3B1, HSD11B2 | LMNA 3468/4885KMT2A 3134/4885MEN1 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.